Skip to content
brainology

Wellness and Longevity Medicine

Can Hearing Aids Protect Brain Health? What the ACHIEVE Trial Really Found

Hearing loss is linked with cognitive decline, but that does not mean it directly causes dementia. The ACHIEVE trial tested whether a comprehensive hearing intervention could slow cognitive change. Its overall result was neutral, while a higher-risk group showed a meaningful benefit. Here is how to interpret those findings.

Conceptual illustration for the achieve trial, with themes of Communication, Trial findings and Risk context.
Brainology editorial illustration. Conceptual, not a patient recording or diagnostic image.

Hearing loss becomes more common with age, and its effects reach beyond missing words in conversation. It can make group settings exhausting, complicate medical visits, and gradually reduce participation in activities that depend on easy communication.

Research has also linked hearing loss with faster cognitive decline and a higher risk of dementia. That has led to an appealing idea: if hearing is treated, could memory and thinking be protected too?

The best answer so far comes from the ACHIEVE randomized trial. Its findings are promising for some older adults, but they are more nuanced than the headline “hearing aids prevent dementia.” The trial did not prove that claim, and its overall primary result was not statistically significant.

Why Hearing Loss and Cognitive Health May Be Connected

Several explanations could connect hearing and cognition. When sound is unclear, the brain must devote more effort to decoding speech, potentially leaving fewer resources for memory and attention. Hearing difficulty may also discourage conversation and social activity. In addition, hearing loss and cognitive decline may share underlying contributors, including aging-related changes and vascular risk factors.

These pathways are plausible, but observational studies cannot determine whether hearing loss directly causes dementia. People who use hearing aids may differ from nonusers in education, income, access to care, general health, and health behaviors. Those differences can influence cognitive outcomes even after researchers adjust for measured factors.

That is why a randomized trial was needed.

What the ACHIEVE Trial Tested

ACHIEVE enrolled 977 adults ages 70 to 84 with untreated mild-to-moderate bilateral hearing loss and without substantial cognitive impairment. Participants came from four U.S. communities and were randomly assigned to one of two programs for three years.

The hearing intervention was more than simply handing someone a device. Participants received hearing aids, individualized fitting, counseling, education, and assistive technologies when needed. The comparison group met with a health educator for a program focused on healthy aging and chronic disease prevention.

Randomization makes the groups more comparable and reduces many of the biases that affect observational research. Still, participants and intervention staff could not be blinded to whether hearing aids were being used, and the trial measured change in cognitive test performance rather than new diagnoses of dementia.

The Main Result Was Neutral Overall

When all 977 participants were analyzed together, the hearing intervention did not significantly slow three-year decline in the trial's global cognition score compared with the health education program.

That overall result matters. It means the study did not show that a comprehensive hearing intervention slows cognitive decline for every older adult with hearing loss over three years.

It also does not prove that hearing treatment has no cognitive value. The trial combined two groups with different baseline levels of health and dementia risk, and the effect differed substantially between them.

A Higher-Risk Group Had a Different Result

About one-quarter of participants, 238 people, had already been followed in the long-running Atherosclerosis Risk in Communities study. This group was older on average and had more risk factors for cognitive decline than the 739 healthier volunteers recruited specifically for ACHIEVE.

In a prespecified analysis, the hearing intervention slowed cognitive decline by 48% over three years in this higher-risk group. In the healthier volunteer group, it did not significantly change cognitive decline.

This subgroup result is clinically important because the difference between the two populations was statistically supported and was planned before the data were analyzed. A 2025 secondary analysis also found greater cognitive benefit among participants who had multiple baseline risk factors associated with faster decline.

Even so, the finding should be interpreted carefully. The higher-risk group was smaller, the trial was not designed to determine whether hearing care prevents dementia, and three years may be too short to capture longer-term effects in healthier adults. Ongoing follow-up may provide a clearer answer.

What the Study Does Not Prove

ACHIEVE does not show that hearing aids prevent Alzheimer's disease or other dementias. It also does not establish that buying an over-the-counter device produces the same cognitive result as the study's comprehensive audiology program.

The reported 48% figure describes a relative difference in the rate of cognitive change between randomized groups within a specific higher-risk population. It is not a 48% reduction in an individual's chance of developing dementia.

The safest conclusion is that treating hearing loss may help slow cognitive decline in older adults who are already at increased risk, while the cognitive benefit for healthier older adults remains uncertain.

Hearing Care Has Benefits Beyond an Uncertain Brain Effect

People do not need to wait for definitive dementia-prevention evidence before addressing hearing loss. In a secondary ACHIEVE analysis, the hearing intervention produced a strong improvement in self-reported communication within six months, and that benefit remained at three years.

Another exploratory analysis found small improvements in social network measures and loneliness. Participants receiving the hearing intervention retained about one additional person in their social network compared with the control group. The researchers cautioned that the clinical meaning of these changes was uncertain and that the loneliness change did not reach a threshold considered clinically meaningful.

The practical goal of hearing care is clearer communication, safer access to information, and fuller participation in daily life. Any possible cognitive protection should be viewed as an additional potential benefit, not a guarantee.

When to Have Your Hearing Checked

Consider a hearing evaluation if you often:

  • struggle to understand speech in restaurants or groups;
  • ask people to repeat themselves;
  • turn the television louder than others prefer;
  • have difficulty hearing on the phone; or
  • feel unusually tired after listening.

An audiologist can measure the type and degree of hearing loss, assess speech understanding, and help match treatment to your needs. A primary care clinician or ear, nose, and throat specialist may also identify reversible or medically important causes such as earwax blockage, infection, medication effects, or middle-ear disease.

Sudden hearing loss, rapidly changing hearing, ear pain or drainage, marked dizziness, or hearing loss or tinnitus mainly in one ear should prompt medical evaluation rather than self-treatment.

OTC or Prescription Hearing Aids?

The U.S. Food and Drug Administration allows over-the-counter hearing aids for adults age 18 and older who perceive mild-to-moderate hearing loss. They do not require a prescription or professional fitting and can improve access for people with straightforward needs.

Prescription hearing aids may be more appropriate when hearing loss is severe, symptoms are uneven between ears, medical warning signs are present, or a person needs individualized programming and support. The most useful device is one that fits comfortably, provides meaningful benefit in real situations, and is worn consistently.

Adjustment takes time. Follow-up can address poor fit, feedback, excessive loudness, difficult phone connections, or limited benefit in noise. If an OTC device does not help enough, that is a reason to seek professional assessment, not simply to give up on hearing care.

The Bottom Line

Hearing aids are not a proven dementia-prevention treatment. The ACHIEVE trial found no significant cognitive benefit across its full study population, but it found substantially slower cognitive decline among participants at higher baseline risk. That signal is encouraging and deserves longer follow-up.

What is already well established is that properly selected hearing treatment can improve communication. For healthy aging, protecting the ability to connect, understand, and participate is a worthwhile goal on its own.

If hearing difficulty is affecting conversations, relationships, or daily activities, Brainology can help coordinate an evidence-based evaluation and discuss whether audiology or medical referral is appropriate. Hearing care should be individualized to symptoms, goals, and overall health rather than treated as a one-size-fits-all strategy for brain health.

This article is for educational purposes and does not replace individualized medical advice. Sudden hearing loss or other urgent symptoms require prompt medical evaluation.

References

  1. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786-797. doi:10.1016/S0140-6736(23)01406-X.
  2. ACHIEVE Study. Key findings: Brain health. Accessed September 19, 2026.
  3. Pike JR, Huang AR, Reed NS, et al. Cognitive benefits of hearing intervention vary by risk of cognitive decline: a secondary analysis of the ACHIEVE trial. Alzheimer's & Dementia. 2025;21(5):e70156. doi:10.1002/alz.70156.
  4. Sanchez VA, Arnold ML, Garcia Morales EE, et al. Effect of hearing intervention on communicative function: a secondary analysis of the ACHIEVE randomized controlled trial. Journal of the American Geriatrics Society. 2024;72(12):3784-3799.
  5. Reed NS, Chen J, Huang AR, et al. Hearing intervention, social isolation, and loneliness: a secondary analysis of the ACHIEVE randomized clinical trial. JAMA Internal Medicine. 2025;185(7):797-806. doi:10.1001/jamainternmed.2025.1140.
  6. National Institute on Deafness and Other Communication Disorders. Age-related hearing loss. Accessed September 19, 2026.
  7. U.S. Food and Drug Administration. OTC hearing aids: What you should know. Accessed September 19, 2026.